Alnylam Pharmaceuticals Inc 's Revenue in the fiscal year 2025 $ 3,713.94 millions
Alnylam Pharmaceuticals Inc 's Revenue in the fiscal year 2024 $ 2,248.24 millions
Alnylam Pharmaceuticals Inc 's Revenue in the fiscal year 2023 $ 1,828.29 millions
Alnylam Pharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 1,037.42 millions
Alnylam Pharmaceuticals Inc 's Revenue in the fiscal year 2021 $ 844.29 millions
ALNY Revenue second quarter 2026 Y/Y Growth Comment
Alnylam Pharmaceuticals Inc achieved in the second quarter 2026, above Company average Revenue rise of 66.86% year on year, to $ 1,290.95 millions.
Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 102 other companies have achieved higher Revenue growth. While Alnylam Pharmaceuticals Inc ' s Revenue jump of 66.86% ranks overall at the positon no. 2086 in the second quarter 2026.
ALNY Revenue ( Y/Y Growth %)
2026
2025
2024
2023
4th Quarter
December
-
84.94 %
34.9 %
31.24 %
3rd Quarter
September
-
149.35 %
-33.26 %
183.96 %
2nd Quarter
June
66.86 %
17.26 %
107.01 %
41.78 %
1st Quarter
March
96.43 %
20.2 %
54.82 %
49.72 %
FY
-
65.19 %
22.97 %
-
Financial Statements
Alnylam Pharmaceuticals Inc 's second quarter 2026 Revenue
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Alnylam Pharmaceuticals Inc 's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
916.58 %
25.25 %
-93.08 %
(Dec 31 2018)
ALNY's II. Quarter Q/Q Revenue Comment
Alnylam Pharmaceuticals Inc achieved in the II. Quarter 2026 below company average Revenue rise of 10.6% quarter on quarter, to $ 1,290.95 millions.
Within Major Pharmaceutical Preparations industry 53 other companies have achieved higher Revenue quarter on quarter growth. While Alnylam Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 788.
Alnylam Pharmaceuticals Inc achieved in the II. Quarter 2026 below company average Revenue rise of 10.6% quarter on quarter, to $ 1,290.95 millions.
Within Major Pharmaceutical Preparations industry 53 other companies have achieved higher Revenue quarter on quarter growth. While Alnylam Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 788.
Alnylam Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Jun 30 2026)
12 Months Ending (Mar 31 2026)
12 Months Ending (Dec 31 2025)
12 Months Ending (Sep 30 2025)
12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending
$ 4,804.18
$ 4,286.92
$ 3,713.94
$ 3,210.07
$ 2,461.96
Y / Y Revenue Growth (TTM)
95.14 %
82.57 %
65.19 %
53.24 %
5.01 %
Year on Year Revenue Growth Overall
Ranking
# 2073
# 827
# 330
# 513
# 17
Seqeuential Revenue Change (TTM)
12.07 %
15.43 %
15.7 %
30.39 %
4.85 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 2090
# 2007
# 1053
# 2575
# 151
Cumulative Revenue growth Comment
Alnylam Pharmaceuticals Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 95.14% year on year, to $ 4,804 millions if the fiscal year would have ended in Jun 30 2026. Alnylam Pharmaceuticals Inc 's trailing twelve months Revenue growth was higher than company's average 41% and higher than 82.57% growth in Mar 31 2026. But from twelve months ended Mar 31 2026 rise was beneth at 12.07 % from $4286.92 millions achieved in the period from Mar 31 2026 to Jun 30 2025. We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at41%. The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 12.07 % increase from $4286.92 millions in the period from Mar 31 2026 to Jun 30 2025.
In the Healthcare sector 311 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 827 to 2073.
Alnylam Pharmaceuticals Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 95.14% year on year, to $ 4,804 millions if the fiscal year would have ended in Jun 30 2026. Alnylam Pharmaceuticals Inc 's trailing twelve months Revenue growth was higher than company's average 41% and higher than 82.57% growth in Mar 31 2026. But from twelve months ended Mar 31 2026 rise was beneth at 12.07 % from $4286.92 millions achieved in the period from Mar 31 2026 to Jun 30 2025. We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at41%. The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 12.07 % increase from $4286.92 millions in the period from Mar 31 2026 to Jun 30 2025.
In the Healthcare sector 311 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 827 to 2073.
About Alnylam Pharmaceuticals Inc Revenue Growth Rates (ALNY), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
115.72%